Buy Cocarboxylase ampoules 50 mg, 5 pcs
  • Buy Cocarboxylase ampoules 50 mg, 5 pcs

Cocarboxylase

Deco Company
922 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$27.19
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Cocarboxylase catalyzes the oxidative decarboxylation of alpha keto acids (pyruvic, alpha ketoglutaric, etc.).

Indications

Metabolic acidosis, hyperglycemic coma and acidosis in diabetes mellitus, hepatic and renal insufficiency, respiratory acidosis in chronic, cardiopulmonary insufficiency, respiratory insufficiency, chronic circulatory insufficiency, ischemic heart disease, myocardial infarction and post-infarction cardio sclerosis (as a part of cardiovascular insufficiency, included in the treatment of myocardial infarction and myocardial infarction and post-infarction cardio sclerosis (as a part of a complex therapy) and chronic alcoholism; poisoning with digitalis, barbiturates, intoxication with infectious diseases: diphtheria, scarlet fever, typhoid and paratyphoid (in combination therapy), peripheral neuritis.

Composition

1 vial with powder for solution for injection contains cocarboxylase hydrochloride 50 mg.

No customer reviews for the moment.

Write your review

Write your review

Cocarboxylase

Dosage and Administration

Cocarboxylase injected s / c, IM. Dose set individually, depending on the nature of the disease and the severity of the patient. Adults: 50-100 mg / day, once, if necessary (diabetic coma) - again after 1-2 hours; in the future, switch to a maintenance dose of 50 mg / day; in case of circulatory failure, 50 mg is administered 2 hours before the use of digitalis preparations, 2-3 times a day. Children per day (1-2 doses): up to 3 months - 25 mg, from 4 months to 7 years - 25-50 mg, from 8 to 18 years - 50-100 mg.

Adverse reactions

Allergic reactions.

Contraindications

Hypersensitivity.

Drug interactions

Due to the presence of pyridoxine (vitamin B6) in the composition, the combined use of levodopa with drugs is contraindicated due to the acceleration of the metabolism of levodopa with the participation of pyridoxine-dependent enzyme. To prevent this interaction, you can use an inhibitor of dopa-decarboxylase - carbidopa.
Due to the presence of folic acid in the formulation, caution should be exercised when used together with antiepileptic drugs containing phenobarbital, phenytoin or primidone. Clinical observation and, if possible, control of the content of antiepileptic drugs in the blood plasma, correction of the dosage regimen of the antiepileptic drug during and after discontinuation of folic acid is necessary.
Compatibility when preparing with other solutions for infusions should be checked, especially if Tsernevit is added to binary parenteral mixtures containing glucose, electrolytes and amino acid solutions, or to mixtures containing glucose, electrolytes, solutions of amino acids and lipids.
The patient should inform the doctor about any drugs that have been used previously.

Special instructions

Due to the presence of glycocholic acid as an excipient, with repeated and long-term administration of the drug in patients with jaundice or severe cholestasis (changes in the laboratory functional tests of the liver), liver function must be carefully monitored.

A deficiency of one or more vitamins should be corrected by administering a deficient vitamin.

Cernevit does not contain vitamin K, which if necessary can be administered separately.

After dilution, the drug is stable at a temperature not higher than 25 ° C for 24 hours, but it is recommended to use the drug immediately after dilution or to store it for no more than 24 hours at a temperature from 2 ° to 8 ° C.

Influence on ability to drive motor transport and control mechanisms

Since Tsernevit is intended for patients who receive parenteral nutrition and are in a severe or moderately severe condition, the ability to drive and work with mechanisms has not been evaluated.

Overdosage

Overdose is predominantly due to excess doses of vitamin A.

Symptoms: in acute overdose of vitamin A (doses in excess of 150 000 ME) - gastrointestinal disorders, headache, increased intracranial pressure, optic nerve edema, mental disorders, excitability, sometimes convulsions, delayed generalized epithelial desquamation; in chronic overdose of vitamin A - an increase in intracranial pressure, cortical hyperostosis and premature fusion of the epiphyseal plate, which is usually expressed in the occurrence of sensitive or painful subcutaneous edema on the fingers of the upper and lower extremities. Radiographic examination of the ulnar, fibula, clavicular and costal bones shows diaphyseal periosteal thickenings.

Treatment: stop the use of the drug, reduce the use of calcium, strengthen diuresis and conduct adequate rehydration of the body.

  • Brand name: Cocarboxylase
  • Active ingredient: Cocarboxylase
  • Dosage form: Lyophilisate for preparation of solution for injections.
  • Manufacturer: Deco Company
  • Country of Origin: Russia

Studies and clinical trials of Cocarboxylase (Click to expand)

  1. Zur Frage des Wirkungsmechanismus des Vitamins B1 und zur Kenntnis der Cocarboxylase
  2. Untersuchungen über die Reaktion von Borsook und Dubnoff II. Der Einfluss der Ketonsäuren und des Ammoniaks; Wirkung der Cocarboxylase
  3. Zur Herstellung der Cocarboxylase und des Aneurin-triphosphorsäure-esters
  4. Beitrag zum Studium der Triphosphorsäureester. Das Verhalten des Thiamin-triphosphorsäureesters und des Thiamin-diphosphorsäureesters (Cocarboxylase) in alkalischer Lösung
  5. Catalytic pre-wave of nickel(II) in presence of cocarboxylase (disulfide form) in borate medium
  6. Polarographic behavior of cocarboxylase in Britton—Robinson buffer
  7. Influence of microwave technology on cocarboxylase hydrochloride particle diversity and drying efficiency
  8. Kinetics and mechanism of the hydrolysis of thiaminepyrophosphate (cocarboxylase)
  9. Binding of dioxouranium(VI) to thiamine and its pyrophosphate ester (Cocarboxylase) in dimethylsulfoxide
  10. Weitere Untersuchungen über den Brenztraubensäurespiegel im Blut und in Hautblasen und dessen Beeinflussung mit Cocarboxylase und Thioctinsäure
  11. Changes in number of cells with chromosomal aberrations in the bone marrow of irradiated mice during combined treatment with cocarboxylase and tryptophan
  12. Effect of atp and cocarboxylase on activity of malate dehydrogenase and its isozymes in blood serum and myocardium
  13. Effect of cocarboxylase on tone of the intracranial and extracranial vessels and on the systemic arterial pressure
  14. Effect of cocarboxylase on some indices of lymphocyte metabolism in newborn rats with experimental asphyxia
  15. Enzymatische Synthese von Cocarboxylase aus Vitamin B1und Phosphat
  16. Das Vorkommen von Aneurin und Cocarboxylase im Liquor
  17. Effect of coenzyme-A, NAD, alpha lipoic-acid and cocarboxylase on survival of rats with galactosamine-induced severe hepatitis
  18. Die Resorption von Cocarboxylase, Riboflavin-5′-phosphat-Natrium und Vitamin A im Colon
  19. Ion-pair reversed-phase HPLC method for the identification and determination of phosphothiamine in cocarboxylase hydrochloride
  20. CARBOXYLASE AND COCARBOXYLASE IN BARLEY
  21. Pyruvic Acid Dehydrogenation, Vitamin B1 and Cocarboxylase

Customers who bought this product also bought:

8 other products in the same category:

arrow_upward